Alexion Pharma

Wilson Therapeutics is a biopharmaceutical company based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. As of 2016, tetrathiomolybdate had been tested in over 500 patients for up to seven years, primarily in oncology and Wilson's disease, as well as some other clinical pathologies.

Wilson Therapeutics

Synageva was a publicly listed biopharmaceutical company headquartered in Lexington, Massachusetts dedicated to discovering, developing and delivering medicines for patients with rare diseases and high unmet medical needs. The company had manufacturing and laboratory locations in Lexington and Holden, Massachusetts, Bogart and Athens Georgia, as well as offices in a variety of locations around the world.

Synageva

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).  In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

Johnson & Johnson

These drugmakers have cornered the markets they need in order to flourish in the long term.

2 Timeless Pharma Stocks to Buy After the Next Market Crash

Alexion's (ALXN) Ultomiris gets approval in Japan for the treatment of adults and children living with atypical hemolytic uremic syndrome.

Alexion's Ultomiris Gets Approval in Japan for Rare Disease

Amgen

Biogen

Gilead Sciences

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The short interest data are out for September 15, the most recent settlement date.

Biotech Short Sellers Hike Their Bets

Alexion (ALXN) gets a positive opinion from the CHMP recommending marketing authorization for a new 100 mg/mL intravenous advanced formulation of Ultomiris in the EU.

Alexion's New Formulation of Ultomiris Gets CHMP Backing

Mattel

This coming weak is likely to be bearish but is also likely to be the end of the September decline.

Stocks This Week: Sell Short Alexion Pharmaceuticals And Mattel

Alexion (ALXN) and partner Caelum Biosciences begin phase III studies on CAEL-101 in AL amyloidosis.

Alexion & Caelum Begin Studies on CAEL-101 in AL Amyloidosis

BOSTON & BORDENTOWN, N.J.--(BUSINESS WIRE)--Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis

Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis

BOSTON--(BUSINESS WIRE)--Alexion to Discuss Key Pipeline Programs at Virtual Investor Day

Alexion to Discuss Key Pipeline Programs at Virtual Investor Day

The short interest data are out for August 31, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Short Sellers Hike Their Bets in Major Biotechs

Royalty Pharma

Although markets have pulled back so far in September, many are viewing this as a technical correction, as the markets ran very hot in a very strong August.

5 Very Undervalued Large Cap Biotech Stocks That Could Explode in 2021

BOSTON--(BUSINESS WIRE)--Alexion Announces Upcoming Data Presentations at MSVirtual2020, the 8th Joint ACTRIMS – ECTRIMS Meeting.

 Alexion Announces Upcoming Data Presentations at MSVirtual2020, the 8th Joint ACTRIMS – ECTRIMS Meeting

Walgreens

Wells Fargo

If getting a good deal is your thing, you're going to love these bargains.

Labor Day Special: 3 Deep-Discount Stocks to Buy Now

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -9% year-to-date versus the S&P 500 which is up by about 7.9% over the same period. The theme remains up by about 45% since the end of 2017, versus 31% for the S&P 500.

Acadia, Novocure & Alexion Stocks Are Out Of Favor, But Promising

Alexion (ALXN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Alexion (ALXN) Catches Eye: Stock Jumps 6.8%

Alexion Pharmaceuticals stock hasn’t moved much this year. But that’s not new.

Alexion Pharmaceuticals: Good Growth But Out Of Favor

Alexion (ALXN) reported earnings 30 days ago. What's next for the stock?

Why Is Alexion (ALXN) Up 2.1% Since Last Earnings Report?

Sirius XM Holdings Inc

Despite gaining over 33% year to date, the high-flying Nasdaq 100 still has value to offer investors.

Got $3,000? Then Buy These Bargain Nasdaq 100 Stocks

CRISPR Therapeutics

Editas Medicine

XBiotech

Biotech stocks are futuristic, but they're also bearing fruit now. So, check out these five hitting on trends and making investors money now.

5 Disruptive Biotech Stocks to Buy for the Future That Is Here

Anthem

Exxon Mobil

Two sectors could see a big boost if Donald Trump earns a second term.

3 Stocks to Buy If You Think Trump Will Win the Election

SSR Mining

Teladoc

History suggests it's only a matter of time before there's another sizable correction in equities.

3 Stocks to Buy When the Stock Market Crashes

Innoviva

These two stocks are probably undervalued, but that won’t last forever.

2 Best Biotech Stocks to Buy in August

BOSTON--(BUSINESS WIRE)--Alexion Announces Appointment of First Chief Diversity Officer

Alexion Announces Appointment of First Chief Diversity Officer

Merck

Pfizer

The biopharmaceutical industry has been one of the most resilient in dealing with the coronavirus pandemic.

5 Large Biotechs and Pharma Stocks Are Dirt Cheap, and Not Because of COVID-19

Pinterest

These companies offer the perfect blend of growth and value.

Got $200? Here Are 3 Smart Stocks to Invest in Now

Investors have flocked to the dividends of Big Pharma and flocked to the limitless upside of major biotech outfits for years.

News for Alexion Pharma Stock (ALXN)